Oryzon Genomics S.A.

Equities

ORY

ES0167733015

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 10:54:01 2024-05-09 am EDT			5-day change	1st Jan Change
1.96 ^EUR	-0.51%		+2.30%	+3.50%

May. 06	Oryzon Genomics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 22	Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat	CI

Oryzon Genomics S.A. Announces Board Changes

May 11, 2020 at 01:19 pm EDT

Oryzon Genomics S.A. announced the appointment of Dr. Manuel López-Figueroa of Bay City Capital as an independent director. Dr. López-Figueroa will be Lead Director and member of the Remuneration and Nomination Committee. Manuel López-Figueroa, PhD, is a Managing Director at Bay City Capital and has been with the firm since 2001. Dr. López-Figueroa replaces Dr. Vanessa Almendro who stepped down the Board due to sudden arisen incompatibility issues with her Firm.

Latest news about Oryzon Genomics S.A.

Oryzon Genomics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat	Apr. 22	CI
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer	Apr. 08	CI
Oryzon Genomics S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 26	CI
Oryzon Genomics, S.A. Announces Topline Results from Phase IIb Portico Study of Vafidemstat in Borderline Personality Disorder	Jan. 05	CI
Oryzon Genomics S.A. announced that it expects to receive ?45 million in funding from Nice & Green SA	Nov. 20	CI
Oryzon Completes Patient Testing in Mid-stage Study of Borderline Personality Disorder Drug	Nov. 07	MT
Oryzon Genomics, S.A. Announces Last Patient Last Visit in Its Phase IIb Portico Study for Borderline Personality Disorder	Nov. 07	CI
Oryzon Genomics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-27	CI
Oryzon Genomics, S.A. Presents Blinded Aggregated Safety Data from Vafidemstat's Ongoing Phase IIB Portico Trial in Borderline Personal Disorder	23-10-10	CI
Oryzon Genomics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-24	CI
Oryzon Genomics, S.A. Reports New Preliminary Blinded Aggregate Safety Data from Its Ongoing Phase IIb Portico Trial	23-07-05	CI
Oryzon Genomics, S.A. Presents Positive Preclinical Data of Ory-4001 for the Treatment of Charcot-Marie-Tooth Disease Presented At the 2023 Peripheral Nerve Society Annual Meeting	23-06-21	CI
Oryzon Genomics, S.A. to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth Disease At the 2023 Peripheral Nerve Society Annual Meeting	23-05-30	CI
Oryzon Genomics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Oryzon Genomics, S.A. Announces Positive Results from Planned Interim Analysis of PORTICO, a Phase 2b Adaptive Trial in Borderline Personality Disorder	23-04-03	CI
Oryzon Announces First Patient in Frida, A Phase Ib Trial with Iadademstat in Relapsed Refractory Flt3-Mutant Acute Myeloid Leukemia Patients	23-03-15	CI
Oryzon Genomics, S.A. Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders	23-03-13	CI
Oryzon Genomics S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-17	CI
Oryzon Genomics S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-17	CI
Oryzon Genomics S.A. announced that it has received €1.800407 million in funding	22-12-19	CI
ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas	22-11-09	CI
Spain's Oryzon Genomics Wins US FDA Nod for Mid-stage Study of Investigational Cancer Drug	22-11-09	MT
Oryzon Genomics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-02	CI
Oryzon Genomics S.A. to Present Preliminary Blinded Aggregate Safety Data from Vafidemstat's Ongoing Phase Iib Portico Trial in Borderline Personality Disorder	22-09-16	CI

Chart Oryzon Genomics S.A.

Duration

Period

More charts

Company Profile

Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The Company also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.

Sector

Biotechnology & Medical Research

Calendar

2024-07-23 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.97 EUR

Average target price

6.694 EUR

Spread / Average Target

+239.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ORYZON GENOMICS S.A.	+3.50%	122M
MODERNA, INC.	+25.36%	46.71B
LONZA GROUP AG	+48.83%	41.8B
IQVIA HOLDINGS INC.	-1.11%	41.52B
CELLTRION, INC.	-3.42%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.41%	25.78B
ALNYLAM PHARMACEUTICALS, INC.	-20.58%	19.26B
BIO-TECHNE CORPORATION	+0.48%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.65%	12.08B
MEDPACE HOLDINGS, INC.	+26.22%	11.98B

Other Biotechnology & Medical Research